GLP-1 Therapies for Addiction: Where the Evidence Stands and What's Needed
Preclinical evidence consistently supports GLP-1 RA efficacy for substance use disorders, observational human data is promising, and RCTs are emerging—but safety, dosing, and mechanisms need clarification.
Quick Facts
What This Study Found
Preclinical evidence consistently supports GLP-1 RA efficacy across alcohol, nicotine, opioid, and psychostimulant use disorders. Observational human data suggest benefits. RCTs are emerging with promising but mixed signals. No increased psychopathology risk.
Key Numbers
How They Did This
Narrative review of preclinical models, observational cohort studies, emerging RCTs, and pharmacovigilance data on GLP-1 therapies for substance use and mental health disorders.
Why This Research Matters
Addiction causes enormous human suffering with few effective medications. GLP-1 drugs are already widely available and could be rapidly repurposed if RCTs confirm efficacy.
The Bigger Picture
The GLP-1 system's involvement in both metabolism and reward processing positions these drugs at the intersection of two major public health crises: metabolic disease and addiction.
What This Study Doesn't Tell Us
Very limited RCT data. Most human evidence is observational. Optimal dose, duration, and individual predictors of response unknown. Mechanisms not fully understood.
Questions This Raises
- ?Which ongoing RCTs are most likely to demonstrate GLP-1 efficacy for addiction?
- ?Will GLP-1 drugs show different efficacy across different substances of abuse?
- ?How can equitable access to GLP-1 addiction treatment be ensured?
Trust & Context
- Key Stat:
- Consistent across substances GLP-1 drugs reduce addictive behaviors for alcohol, nicotine, opioids, and psychostimulants in preclinical models
- Evidence Grade:
- Narrative review integrating preclinical, observational, and limited RCT evidence. Strong rationale with emerging but not yet definitive clinical proof.
- Study Age:
- Published in 2025, at a pivotal time for GLP-1 addiction research.
- Original Title:
- Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.
- Published In:
- JAMA psychiatry, 83(3), 306-314 (2026)
- Authors:
- Farokhnia, Mehdi(8), Leggio, Lorenzo(9)
- Database ID:
- RPEP-15153
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs like Ozempic help with addiction?
Animal studies strongly suggest yes, and human observational data is promising. Clinical trials are underway but haven't definitively proven it yet. GLP-1 drugs should not be prescribed specifically for addiction until trial results are available.
Do GLP-1 drugs cause depression or suicidal thoughts?
Despite early pharmacovigilance concerns, the evidence reviewed here suggests GLP-1 drugs do not increase the risk of depression or suicidal ideation. Some studies even suggest beneficial mental health effects.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15153APA
Farokhnia, Mehdi; Leggio, Lorenzo. (2026). Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.. JAMA psychiatry, 83(3), 306-314. https://doi.org/10.1001/jamapsychiatry.2025.4308
MLA
Farokhnia, Mehdi, et al. "Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.." JAMA psychiatry, 2026. https://doi.org/10.1001/jamapsychiatry.2025.4308
RethinkPeptides
RethinkPeptides Research Database. "Prospects of GLP-1 Therapies for Addiction and Mental Health..." RPEP-15153. Retrieved from https://rethinkpeptides.com/research/farokhnia-2026-prospects-of-glp1-therapies
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.